Charles Explorer logo
🇬🇧

Predictors of sustained response to infliximab in patients with Crohn´s disease: a single cohort study

Publication

Abstract

Sustained response to IFX was observed in about two thirds of CD patients. Therapeutic IFX levels at start of maintenance regime and concomitant immunosuppressive therapy were associated with sustained clinical benefit, whereas need for corticosteroids at IFX initiation increased the risk of IFX failure.